Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) following Q4 results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: CMPX) | Delayed: 0.76 +0.01 (1.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.75 | 52 Week High | $ | |||
| Open | $0.78 | 52 Week Low | $ | |||
| Day High | $0.80 | P/E | N/A | |||
| Day Low | $0.75 | EPS | $ | |||
| Volume | 1,861,985 | |||||
